MHRAsafety guidance83% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Astellas Pharma.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Oncology · NSCLC
- Sub-indication
- Lung Cancer
Related signal: Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma